The anecdotal use of anti-EGFR therapy with cetuximab in HDGC patients with advanced gastric cancers applied by some medical oncologists in the field appears to be in line with the detected sensitivities to EGFR, PI3K and MEK inhibition as well as elevation of MAPK kinase signaling in c.1380delA CDH1 SB.mhdgc-1 cells. The gene discussed is EGFR; the disease is gastric cancer.